Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Lukas Kazianka, Tea Pemovska, Johannes Rohrbeck, Christoph Kornauth, Alexander Pichler, Christiane Agreiter, Simone Lubowitzki, Katharina Prochazka, Peter Neumeister, Clemens Schmitt, Richard Greil, Wolfgang Willenbacher, Dominik Wolf, Ulrich Jaeger, Ingrid Simonitsch-Klupp, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2023-189856

Published: 2023

Journal Articles

The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax

Marta M. Szmyra, Sandra Haingartner, Sonja Jantscher, Katrin Pansy, Barbara Uhl, Hildegard T. Greinix, Peter Neumeister, Eva Bernhart, Christine Beham-Schmid, Michael A. Dengler, Burkhard Klösch, Alexander J.A. Deutsch

Blood (2022) 140 (Supplement 1): 4945–4946.

https://doi.org/10.1182/blood-2022-166678

Published: 2022

Journal Articles

Loss of Nr4a1 Causes an Elevated Expression of Co-Inhibitory Receptor:Ligand Axes and Results in a Diminished T Cell-Mediated Lymphoma Cell Killing in Aggressive Lymphoma

Katrin Pansy, Karoline Fechter, Kerstin Wenzl, Aditya Arra, Joseph P. Novak, Marta Szmyra, Sandra Haingartner, Alan G. Ramsay, Anne J. Novak, Hildegard T. Greinix, Christine Beham-Schmid, Peter Neumeister, Alexander J.A. Deutsch

Blood (2022) 140 (Supplement 1): 2038–2039.

https://doi.org/10.1182/blood-2022-163034

Published: 2022

Journal Articles

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Jakob D. Rudzki, Ulrich Jaeger, Dominik Wolf, Andreas Petzer, Richard Greil, Christina Peters, Hildegard T. Greinix, Andishe Attarbaschi, Veronika Buxhofer-Ausch, Michael Girschikofsky, Wolfgang Holter, Michael Leisch, Peter Neumeister, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Nina Worel, Philipp Wohlfarth

Blood (2022) 140 (Supplement 1): 6661–6663.

https://doi.org/10.1182/blood-2022-167603

Published: 2022

Journal Articles

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Ulrich Jaeger, MD, Alexander Egle, MD, Ingrid Simonitsch-Klupp, MD, Sonja Heibl, MD, Peter Neumeister, MD, Ella Willenbacher, MD, Florian Erlsbacher, Julian Larcher-Senn, Michael A. Fridrik, MD, Richard Greil, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-136953

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

https://doi.org/10.1182/blood-2019-128388

Published: 2019

Journal Articles

Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL

Katrin Pansy, MSc, BSc, Julia Feichtinger, Barbara Ehall, Barbara Uhl, Hildegard T. Greinix, MD, Katharina Prochazka, MD, Christine Beham-Schmid, Peter Neumeister, MD, Tanja Wrodnigg, Karoline Fechter, Alexander Deutsch

Blood (2019) 134 (Supplement_1): 1519.

https://doi.org/10.1182/blood-2019-130029

Published: 2019

Journal Articles

Evaluation of Clinical and Morphological Practices in the Diagnosis of Transplant-Associated Microangiopathy: A Study on Behalf of the Complications and Quality of Life Working Party of the EBMT

Blood (2017) 130 (Supplement 1): 1958.

https://doi.org/10.1182/blood.V130.Suppl_1.1958.1958

Published: 2017

Journal Articles

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis

Kinkini N. Magina, Gudrun Pregartner, Armin Zebisch, Albert Wölfler, Peter Neumeister, Hildegard T. Greinix, Andrea Berghold, Heinz Sill

Blood (2017) 130 (7): 946–948.

https://doi.org/10.1182/blood-2017-04-777722

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil, Markus Raderer

Blood (2017) 129 (3): 383–385.

https://doi.org/10.1182/blood-2016-06-720599

Published: 2017

Journal Articles

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Michael Panny, MD, Katharina Troppan, MD, Peter Neumeister, MD, Thomas Nösslinger, MD, Felix Keil, MD

Blood (2016) 128 (22): 5413.

https://doi.org/10.1182/blood.V128.22.5413.5413

Published: 2016

Journal Articles

NR4A3 Suppresses Lymphomagenesis I n Vitro and In Vivo by Induction of Similar Patterns of Pro-Apoptotic Genes like NR4A1

Alexander JA Deutsch, PhD, Beate Rinner, Martin Pichler, Karoline Fechter, Hildegard T. Greinix, MD, Chenguang Wang, Christine Beham-Schmid, MD, Peter Neumeister, MD

Blood (2016) 128 (22): 2728.

https://doi.org/10.1182/blood.V128.22.2728.2728

Published: 2016

Journal Articles

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

Kerstin Wenzl, MSc, Katharina Troppan, MD, Beata Pursche, Marco Bischof, Christine Beham-Schmid, MD, Hildegard T. Greinix, MD, Peter Neumeister, MD, Alexander JA Deutsch, PhD

Blood (2015) 126 (23): 2444.

https://doi.org/10.1182/blood.V126.23.2444.2444

Published: 2015

Journal Articles

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

Barbara Kiesewetter, MD, Richard Greil, MD, Wolfgang Willenbacher, MD, Peter Neumeister, MD, Michael A. Fridrik, MD, Raderer Markus, MD

Blood (2015) 126 (23): 3973.

https://doi.org/10.1182/blood.V126.23.3973.3973

Published: 2015

Journal Articles

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

Katharina Troppan, MD, Kerstin Wenzl, MSc, Peter Neumeister, MD, Christine Beham-Schmid, MD, Martina Przekopowitz, Hildegard T. Greinix, MD, Helmut Schaider, MD, Alexander JA Deutsch, PhD

Blood (2015) 126 (23): 3890.

https://doi.org/10.1182/blood.V126.23.3890.3890

Published: 2015

Journal Articles

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

Alexander JA Deutsch, PhD, Beate Rinner, PhD, Kerstin Wenzl, MSc, Katharina Troppan, MD, Beata Pursche, Hildegard T. Greinix, MD, Christine Beham-Schmid, MD, Peter Neumeister, MD

Blood (2015) 126 (23): 2674.

https://doi.org/10.1182/blood.V126.23.2674.2674

Published: 2015

Journal Articles

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

Blood (2015) 125 (7): 1091–1097.

https://doi.org/10.1182/blood-2014-07-587089

Published: 2015

Includes: Supplemental data

Journal Articles

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Alexander J. A. Deutsch, Beate Rinner, Kerstin Wenzl, Martin Pichler, Katharina Troppan, Elisabeth Steinbauer, Daniela Schwarzenbacher, Sonja Reitter, Julia Feichtinger, Sascha Tierling, Andreas Prokesch, Marcel Scheideler, Anne Krogsdam, Gerhard G. Thallinger, Helmut Schaider, Christine Beham-Schmid, Peter Neumeister

Blood (2014) 123 (15): 2367–2377.

https://doi.org/10.1182/blood-2013-08-518878

Published: 2014

Includes: Supplemental data

Journal Articles

Novel face of microRNA-155

Peter Neumeister, Heinz Sill

Blood (2014) 123 (1): 5–7.

https://doi.org/10.1182/blood-2013-11-534107

Published: 2014

NARROW

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax

Loss of Nr4a1 Causes an Elevated Expression of Co-Inhibitory Receptor:Ligand Axes and Results in a Diminished T Cell-Mediated Lymphoma Cell Killing in Aggressive Lymphoma

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL

Evaluation of Clinical and Morphological Practices in the Diagnosis of Transplant-Associated Microangiopathy: A Study on Behalf of the Complications and Quality of Life Working Party of the EBMT

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

NR4A3 Suppresses Lymphomagenesis I n Vitro and In Vivo by Induction of Similar Patterns of Pro-Apoptotic Genes like NR4A1

Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis

AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)

The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome

NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas

Novel face of microRNA-155

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only